BNTX analyst estimates
BioNTech (BNTX) analyst ratings, the average price target and its range, and every firm's latest call.
BNTX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 14, 2026 | Canaccord Genuity | BioNTech price target lowered to $132 from $136 at Canaccord | $132.00 |
| Oct 7, 2026 | Morgan Stanley | BioNTech price target lowered to $114 from $115 at Morgan Stanley | $114.00 |
| Sep 16, 2026 | Berenberg Bank | BioNTech price target raised to $140 from $132 at Berenberg | $140.00 |
| Sep 8, 2026 | BMO Capital | BMO Capital Downgrades BioNTech (BNTX) to Market Perform | $105.00 |
| Aug 31, 2026 | Canaccord Genuity | BioNTech price target lowered to $136 from $142 at Canaccord | $136.00 |
| Aug 5, 2026 | Canaccord Genuity | BioNTech price target raised to $142 from $138 at Canaccord | $142.00 |
| Jul 8, 2026 | Morgan Stanley | BioNTech price target lowered to $119 from $126 at Morgan Stanley | $119.00 |
| May 27, 2026 | UBS | BioNTech upgraded to Buy from Neutral at UBS | $135.00 |
| May 21, 2026 | Bernstein | BioNTech initiated with a Market Perform at Bernstein | $96.00 |
| May 6, 2026 | Canaccord Genuity | BioNTech price target lowered to $158 from $171 at Canaccord | $158.00 |
| Apr 10, 2026 | Morgan Stanley | BioNTech price target raised to $126 from $125 at Morgan Stanley | $126.00 |
| Mar 11, 2026 | BMO Capital | BioNTech (BNTX) PT Lowered to $128 at BMO Capital | $128.00 |
| Mar 10, 2026 | Morgan Stanley | BioNTech (BNTX) PT Lowered to $128 at BofA Securities | $128.00 |
| Mar 10, 2026 | Truist Financial | Truist Securities Reiterates Buy Rating on BioNTech (BNTX) following earnings, management changes | $155.00 |
| Mar 10, 2026 | Jefferies | BioNTech (BNTX) PT Lowered to $138 at Jefferies | $138.00 |
- 12 firms rate BNTX: 9 buy, 3 hold, 0 sell.
- The average price target is $120.33 from 6 analysts, from $96.00 to $140.00.
Updated 2026-11-02 23:12 UTC